NCT04034745View on ClinicalTrials.gov

Open Label Study to Analyze the Effect of Telotristat Ethyl on Weight Regulation/Gain

WithdrawnOBSERVATIONAL
0
Timeline

Start Date

October 31, 2020

Primary Completion Date

November 30, 2022

Study Completion Date

November 30, 2023

Conditions
Pancreatic CancerNeuroendocrine TumorsCachexia; Cancer
Interventions
DRUG

telotristat ethyl

250 mg tablets of Xermelo (telotristat ethyl) is administered orally 3x daily in combination with somatostatin analogs (SSAs) for approximately 84 days as per standard of care

Sponsors

Collaborators (1)

Lexicon Pharmaceuticals
All Listed Sponsors
collaborator

Lexicon Pharmaceuticals

INDUSTRY

lead

Andrew Hendifar, MD

OTHER